Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Cash (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Change in Cash data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Change in Cash fell 73.46% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $148.8 million, up 261.59%, while the annual FY2025 figure was $148.8 million, 261.59% up from the prior year.
  • Change in Cash reached $1.5 million in Q4 2025 per AMLX's latest filing, down from $166.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $166.6 million in Q3 2025 and bottomed at -$112.5 million in Q3 2023.
  • Average Change in Cash over 5 years is $10.7 million, with a median of $913000.0 recorded in 2024.
  • The widest YoY moves for Change in Cash: up 6934.5% in 2025, down 5121.08% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$26.5 million in 2021, then crashed by 70.69% to -$45.2 million in 2022, then skyrocketed by 177.29% to $34.9 million in 2023, then plummeted by 84.1% to $5.6 million in 2024, then plummeted by 73.46% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $1.5 million in Q4 2025, $166.6 million in Q3 2025, and -$1.7 million in Q2 2025.